This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Last week, I documented that nearly half of U.S. pharmacies now participate in the 340B Drug Pricing Program. Below, we update our exclusive analysis of the biggest specialtypharmacies within 340B. As you will see below, these specialtypharmacies have dramatically increased their participation in the 340B program.
Launched in 2019, NABP’s SpecialtyPharmacy Accreditation was created to accredit pharmacies providing advanced levels of pharmacy services and disease management tools for patients taking medications that require special handling, storage, and dispensing requirements.
Customized 340B software should be able to automatically document the journey of every eligible prescription written — from the providers to the retail and specialty contract pharmacies, and from billing to claiming-and-qualifying for 340B reimbursement. For an overview of SpecialtyPharmacy Best Practices, Click Here.
Between late 2019 and the end of 2023, ProxsysRx’s 340B Support program went from Zero to more than $500 million in savings generated for the hospitals and health systems we serve. Understand, and master, your 340B specialtypharmacy opportunities. The 340B revenue potential of specialtypharmacy is staggering.
The NHC requests more clarity on how CMS will exclude QALY-based metrics and highlight when they have been removed from consideration in MFP justification documentation. Pharmacy benefit managers: transparency, accountability, and impact on patient care. Journal of Managed Care & SpecialtyPharmacy, 27(7), 903-907.
A 2019 study highlighted that physicians’ biases could influence their clinical decision-making, which underscores the importance of awareness and training to mitigate such biases.15 15 The NHC advocates for rigorous, transparent documentation of the medical rationale in such instances to prevent discriminatory practices.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content